FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899341288> ?p ?o ?g. }

• W2899341288 abstract "Abstract Background The increase in multidrug resistant Plasmodium falciparum infections threatens the malaria elimination goals in countries within the Greater Mekong Sub-region. A multi-pronged approach assuring access to basic malaria control measures, including insecticide-treated bed nets and early diagnosis and treatment was followed by mass drug administrations (MDA) in southern Savannakhet Province, Laos. The main objective of this study was to evaluate the effectiveness and safety of mass drug administrations as well as their effects on the dynamic of asymptomatic P. falciparum infections in 4 malaria endemic villages. Methods Two villages were randomized to early MDA consisting of 3 rounds of a 3-day course of dihydroartemisinin–piperaquine with a single low dose of primaquine. In the other 2 villages MDA was deferred by 1 year. A total of 1036 residents were enrolled in early MDA villages and 883 in control villages (deferred-MDA). Tri-monthly parasitaemia surveys using uPCR were conducted for a year in the 4 villages. Results Eighty-four percent (872/1036) of the residents participated in the MDAs, of whom 90% (781/872) completed 3 rounds of MDA (9 doses). In intervention villages, the prevalence of asymptomatic P. falciparum infections decreased by 85% after MDA from 4.8% (95% CI 3.4–6.4) at baseline (month 0 or M0) to 0.7% (95% CI 0.3–1.6) at month 12. In control villages there was a decrease of 33% in P. falciparum prevalence between M0: 17.5% (95% CI 15.9–20.3) and M12: 11.6% (95% CI 9.3–14.2). In bivariate and multivariate analyses P. falciparum infections were significantly reduced with early MDA (adjusted incidence rate ratios (AIRR): 0.08, CI 0.01–0.091) and completion of 3 MDA rounds (AIRR: 0.06; CI 0.01–0.66). A quarter of participants (226/872) reported adverse events of which 99% were mild. Conclusion The study found a significant reduction in P. falciparum prevalence and incidence following MDA. MDA was safe, well tolerated, feasible, and achieved high population coverage and adherence. MDAs must be integrated in multi-pronged approaches such as vector control and preventive measures with a focus on specific risk groups such as mobile, migrant population and forest goers for a sustained period to eliminate the remaining parasite reservoirs. Trial registration ClinicalTrials.gov Identifier: NCT01872702" @default.
• W2899341288 created "2018-11-09" @default.
• W2899341288 creator A5007007103 @default.
• W2899341288 creator A5011726781 @default.
• W2899341288 creator A5013453998 @default.
• W2899341288 creator A5015328387 @default.
• W2899341288 creator A5015725563 @default.
• W2899341288 creator A5021308180 @default.
• W2899341288 creator A5024446909 @default.
• W2899341288 creator A5028227666 @default.
• W2899341288 creator A5029292055 @default.
• W2899341288 creator A5032394349 @default.
• W2899341288 creator A5034097318 @default.
• W2899341288 creator A5051408897 @default.
• W2899341288 creator A5058736493 @default.
• W2899341288 creator A5060343662 @default.
• W2899341288 creator A5061199563 @default.
• W2899341288 creator A5072761854 @default.
• W2899341288 creator A5084217335 @default.
• W2899341288 date "2018-11-03" @default.
• W2899341288 modified "2023-10-17" @default.
• W2899341288 title "The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin–piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos" @default.
• W2899341288 cites W1979668339 @default.
• W2899341288 cites W2112222406 @default.
• W2899341288 cites W2114625697 @default.
• W2899341288 cites W2116713035 @default.
• W2899341288 cites W2122683268 @default.
• W2899341288 cites W2165691527 @default.
• W2899341288 cites W2171102256 @default.
• W2899341288 cites W2404643383 @default.
• W2899341288 cites W2549012749 @default.
• W2899341288 cites W2560080836 @default.
• W2899341288 cites W2584480708 @default.
• W2899341288 cites W2751699411 @default.
• W2899341288 cites W2755806578 @default.
• W2899341288 cites W2766190655 @default.
• W2899341288 cites W2783983357 @default.
• W2899341288 cites W2802085197 @default.
• W2899341288 cites W2889248076 @default.
• W2899341288 doi "https://doi.org/10.1186/s12936-018-2541-9" @default.
• W2899341288 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6215638" @default.
• W2899341288 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30390647" @default.
• W2899341288 hasPublicationYear "2018" @default.
• W2899341288 type Work @default.
• W2899341288 sameAs 2899341288 @default.
• W2899341288 citedByCount "19" @default.
• W2899341288 countsByYear W28993412882019 @default.
• W2899341288 countsByYear W28993412882020 @default.
• W2899341288 countsByYear W28993412882021 @default.
• W2899341288 crossrefType "journal-article" @default.
• W2899341288 hasAuthorship W2899341288A5007007103 @default.
• W2899341288 hasAuthorship W2899341288A5011726781 @default.
• W2899341288 hasAuthorship W2899341288A5013453998 @default.
• W2899341288 hasAuthorship W2899341288A5015328387 @default.
• W2899341288 hasAuthorship W2899341288A5015725563 @default.
• W2899341288 hasAuthorship W2899341288A5021308180 @default.
• W2899341288 hasAuthorship W2899341288A5024446909 @default.
• W2899341288 hasAuthorship W2899341288A5028227666 @default.
• W2899341288 hasAuthorship W2899341288A5029292055 @default.
• W2899341288 hasAuthorship W2899341288A5032394349 @default.
• W2899341288 hasAuthorship W2899341288A5034097318 @default.
• W2899341288 hasAuthorship W2899341288A5051408897 @default.
• W2899341288 hasAuthorship W2899341288A5058736493 @default.
• W2899341288 hasAuthorship W2899341288A5060343662 @default.
• W2899341288 hasAuthorship W2899341288A5061199563 @default.
• W2899341288 hasAuthorship W2899341288A5072761854 @default.
• W2899341288 hasAuthorship W2899341288A5084217335 @default.
• W2899341288 hasBestOaLocation W28993412881 @default.
• W2899341288 hasConcept C126322002 @default.
• W2899341288 hasConcept C142724271 @default.
• W2899341288 hasConcept C185032368 @default.
• W2899341288 hasConcept C190612196 @default.
• W2899341288 hasConcept C203014093 @default.
• W2899341288 hasConcept C2776120307 @default.
• W2899341288 hasConcept C2776793103 @default.
• W2899341288 hasConcept C2777425658 @default.
• W2899341288 hasConcept C2777616469 @default.
• W2899341288 hasConcept C2777910003 @default.
• W2899341288 hasConcept C2778048844 @default.
• W2899341288 hasConcept C2778371730 @default.
• W2899341288 hasConcept C2780133432 @default.
• W2899341288 hasConcept C2908647359 @default.
• W2899341288 hasConcept C71924100 @default.
• W2899341288 hasConcept C99454951 @default.
• W2899341288 hasConceptScore W2899341288C126322002 @default.
• W2899341288 hasConceptScore W2899341288C142724271 @default.
• W2899341288 hasConceptScore W2899341288C185032368 @default.
• W2899341288 hasConceptScore W2899341288C190612196 @default.
• W2899341288 hasConceptScore W2899341288C203014093 @default.
• W2899341288 hasConceptScore W2899341288C2776120307 @default.
• W2899341288 hasConceptScore W2899341288C2776793103 @default.
• W2899341288 hasConceptScore W2899341288C2777425658 @default.
• W2899341288 hasConceptScore W2899341288C2777616469 @default.
• W2899341288 hasConceptScore W2899341288C2777910003 @default.
• W2899341288 hasConceptScore W2899341288C2778048844 @default.
• W2899341288 hasConceptScore W2899341288C2778371730 @default.
• W2899341288 hasConceptScore W2899341288C2780133432 @default.
• W2899341288 hasConceptScore W2899341288C2908647359 @default.
• W2899341288 hasConceptScore W2899341288C71924100 @default.
• W2899341288 hasConceptScore W2899341288C99454951 @default.

• next